{"filing":{"accession_number":"0001708599-26-000043","cik":"0001708599","ticker":"SER","company_name":"Serina Therapeutics, Inc.","form":"8-K","filing_date":"2026-07-22","report_date":null,"primary_document":"ser-20260723xappointmentof.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1708599/000170859926000043/ser-20260723xappointmentof.htm"},"events":[{"id":19658,"run_id":17689,"accession_number":"0001708599-26-000043","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The filing discloses the appointment of Farrell Simon, Pharm.D., to Serina's Board of Directors effective July 22, 2026, with concurrent appointment to the Audit and Compensation Committees. Dr. Simon brings significant commercial and business development expertise from his role as Chief Commercial Officer at Trevi Therapeutics and prior decade at Pfizer, making this a material governance event affecting board composition and oversight capabilities at a clinical-stage biotech company.","company_name":"Serina Therapeutics, Inc.","ticker":"SER","filing_date":"2026-07-22","form":"8-K","submitted_at":null,"items":[{"id":18808,"accession_number":"0001708599-26-000043","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Farrell Simon, Pharm.D., to Serina's Board of Directors effective July 22, 2026, with concurrent appointment to the Audit and Compensation Committees. Dr. Simon brings significant commercial and business development expertise from his role as Chief Commercial Officer at Trevi Therapeutics and prior decade at Pfizer, making this a material governance event affecting board composition and oversight capabilities at a clinical-stage biotech company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-22T21:04:41.227752+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":18808,"accession_number":"0001708599-26-000043","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Farrell Simon, Pharm.D., to Serina's Board of Directors effective July 22, 2026, with concurrent appointment to the Audit and Compensation Committees. Dr. Simon brings significant commercial and business development expertise from his role as Chief Commercial Officer at Trevi Therapeutics and prior decade at Pfizer, making this a material governance event affecting board composition and oversight capabilities at a clinical-stage biotech company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-22T21:04:41.227752+00:00","company_name":"Serina Therapeutics, Inc.","ticker":"SER","filing_date":"2026-07-22"}]}